For more insights on the intersection of AI and healthcare,?visit our website
?and?subscribe
?for regular updates.?
Discoveries to strategic collaborations, here's a snapshot of the past week's most notable events. Stay ahead with these key updates.
AI Policy & Standards in Healthcare
-
CloudWave
releases a comprehensive framework for the management of artificial intelligence technologies in healthcare, including policies and procedures on risk assessment, ethical considerations, data governance, and more.
- The policies align with existing standards such as HIPAA, NIST CSF, and NIST 800-53 and emphasize creating a culture of continuous security, safety, and adaptability to evolving technology and regulations.?
AI in Diagnostics & Imaging
- A publication by Nature found that deep learning shows promising potential in diagnosing and monitoring common skin diseases, with high accuracy rates in conditions such as acne, rosacea, eczema, and psoriasis.
- However, the same publication highlighted concerns: the majority of the reviewed studies had a high risk-of-bias and applicability concerns. Nature emphasizes the necessity for real-world, prospectively-acquired datasets and external validation for the broader application and validation of deep learning in dermatology.
-
西门子医疗
introduces the Mammomat B.brilliant, a mammography system capable of completing a 3D breast cancer scan in about five seconds, leveraging AI reconstruction software and flying focal spot technology to enhance image clarity.
- The company also received FDA approval for its Magnetom Viato.Mobile
, a 1.5T mobile MRI system that offers equivalent imaging performance to stationary units, designed for flexibility in both transportation and stationary usage.
-
Exo
, established in 2015, introduces its handheld ultrasound system, Iris, integrating AI and patented pMUT technology, aiming to revolutionize diagnostic imaging.
- Iris, priced at a starting rate of $3,500 in the U.S., offers a 150-degree field of view, a depth of 30 centimeters, and the ability to switch between various arrays without changing probes. This versatile capability stands in contrast to traditional systems costing between $5,000 and $200,000.?
AI-Driven Drug Discovery & Development?
-
诺和诺德
collaborates with
Valo Health
to employ artificial intelligence in identifying new cardiovascular disease drug treatments.
- The partnership grants Novo Nordisk access to Valo’s Opal Computational Platform, enhancing the discovery and development process with real-world patient data and AI-driven discovery tools.
- In addition to the $60 million upfront payment to Valo, the agreement stipulates the potential for up to $2.7 billion in future payments and potential royalties, as the companies strive to gain novel insights from CVD patient data.
-
Merck KGaA, Darmstadt, Germany
deepens its collaboration with Quris-AI to leverage the BioAI platform for drug toxicity prediction, aiming to reduce dependence on animal testing.
- This expansion follows Merck's recent AI-focused partnerships with
BenevolentAI
and
Exscientia
, highlighting its commitment to AI in drug discovery and development.
-
Deep Genomics
' BigRNA employs AI to predict RNA expression regulatory mechanisms, aiding in understanding how gene variants result in diseases and pinpointing sites for new drug development.
- Constructed from 1 trillion genomic signals and featuring 1.8 billion adjustable parameters, BigRNA has demonstrated potential in designing treatments for conditions like Wilson disease and spinal muscular atrophy.
-
Evozyne
secures $81m in a Series B round led by
OrbiMed
and
Fidelity Management And Research Company
, focusing on its generative AI platform to simulate protein evolution and enhance drug discovery.
-
英伟达
, a leading force in generative AI, supported Evozyne with a pre-trained AI model, highlighting the transformative potential of generative AI in speeding up the drug discovery process and improving efficiency.
AI Funding & Expansion
-
Thirona
raises €7.5 Million to boost its AI technology focused on advanced thoracic CT image analysis and improve medical treatment pathways for lung diseases.
- The company's LungQ? platform, having analyzed over 15 million images, is set to revolutionize personalized treatment and drive advancements in precision medicine for lung diseases.
AI in Real-World Applications
-
The City College of New York
secures a four-year $2.8 million
National Science Foundation (NSF)
grant for a project aimed at creating an AI and Machine Learning (AI/ML) system for early diagnosis of cardiovascular disease.
- The initiative, in partnership with
美国俄亥俄州立大学
's AI-EDGE Institute, will produce a cost-effective and high-precision diagnostic tool that uses multimodal sensors for real-time monitoring and personalized learning technologies to ensure accuracy.
- The project also focuses on community engagement, especially targeting under-represented minority communities, and offers diverse training opportunities for CCNY students, ranging from undergraduates to post-doctorates.
-
纽昂司
, owned by
微软
, introduces its AI-backed DAX Copilot tool, which instantly drafts clinical summaries of patient conversations. This builds upon Nuance’s previous documentation tool, DAX, but is fully automated and integrated with the GPT-4 language model.
- The rapid emergence of generative AI in healthcare aims to reduce administrative burdens for providers. However, concerns about accuracy, bias, and rapid deployment without adequate oversight have been raised by experts.
-
英伟达
supports the emergence of Invenio, a new medtech startup aiming to leverage AI for quick evaluations of biopsies in operating rooms, bypassing the traditional weeks-long pathology lab process.
-
invenio
's innovative imaging system, powered by NVIDIA's Jetson AI tool, seeks to provide surgeons with biopsy results within three minutes, facilitating faster and more informed intraoperative decisions, including potential personalized medical treatment diagnoses.
Leadership Insights & Announcements?
- President Biden underscores the transformative potential of AI in healthcare, referencing global discussions on AI's responsible use and stressing the urgency of harnessing its power safely and innovatively.
- Biden announces major
Advanced Research Projects Agency for Health (ARPA-H)
investments to counter drug-resistant bacteria and emphasizes the crucial role of patient safety and high-quality care across all American communities.
More about Intelligence Ventures
We are an emerging venture capital firm dedicated to cultivating innovation at the intersection of artificial intelligence and healthcare within the United States. Our commitment lies in the strategic investment and nurturing of pre-seed, seed, and Series A companies, fueling their growth and fostering the next generation of industry leaders.
Our initial fund, AI Health Fund I, is focused on companies that use artificial intelligence to increase efficiencies and/or solve computationally intractable problems that place a ceiling on our ability to develop new drugs, advance them through clinical trials, and ultimately diagnose and treat patients. We are industry vertical agnostic and believe that generative AI and more specific ML models can be used to accelerate innovation in biotech, pharma, medtech, and diagnostics.
For more information, visit our website at?www.intelligencevc.com
?or reach out to?[email protected]
?for any inquiries. Be sure to follow us on?LinkedIn
?and?Twitter
, and?subscribe
?for further installments of?The Intelligence Report
.
